Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.
暂无分享,去创建一个
[1] R. Boucher. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. , 2007, Annual review of medicine.
[2] Garry R. Cutting,et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders , 2008, Genetics in Medicine.
[3] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[4] P. Zeitlin. Future Pharmacological Treatment of Cystic Fibrosis , 2000, Respiration.
[5] P. Negulescu,et al. Rescue of the protein folding defect in cystic fibrosis in vitro by the investigational small molecule, VX-809 , 2010 .
[6] A. Bush,et al. Cystic fibrosis in the 21st century , 2005 .
[7] M. Welsh,et al. Processing and function of CFTR-ΔF508 are species-dependent , 2007, Proceedings of the National Academy of Sciences.
[8] David K Meyerholz,et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. , 2010, The Journal of clinical investigation.
[9] Eitan Kerem,et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial , 2008, The Lancet.
[10] Scott H Randell,et al. Well-differentiated human airway epithelial cell cultures. , 2005, Methods in molecular medicine.
[11] G. Cutting,et al. Update on gene modifiers in cystic fibrosis , 2008, Current opinion in pulmonary medicine.
[12] P. Quinton. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis , 2008, The Lancet.
[13] F. Vermeulen,et al. Ataluren (PTC124) Induces CFTR Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis , 2010 .
[14] A. Moran,et al. Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality , 2009, Diabetes Care.
[15] Roberto Ravazzolo,et al. TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel Activity , 2008, Science.
[16] Margaret Rosenfeld,et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. , 2002, American journal of respiratory and critical care medicine.
[17] P. Sly,et al. Disease surveillance using bronchoalveolar lavage. , 2008, Paediatric respiratory reviews.
[18] E. Sakmar,et al. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease , 2010, Pediatric pulmonology.
[19] J. Riordan,et al. CFTR function and prospects for therapy. , 2008, Annual review of biochemistry.
[20] E. Alton,et al. Cystic fibrosis gene therapy: successes, failures and hopes for the future , 2009, Expert review of respiratory medicine.
[21] T. Waldhör,et al. Perspectives of longitudinal growth in cystic fibrosis from birth to adult age , 1994, European Journal of Pediatrics.
[22] C. Milla,et al. Nutrition in cystic fibrosis. , 2009, Seminars in respiratory and critical care medicine.
[23] M. Drumm,et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis , 2009, Diabetologia.
[24] P. Pedersen,et al. Altered protein folding may be the molecular basis of most cases of cystic fibrosis , 1992, FEBS letters.
[25] C. Penland,et al. Cystic fibrosis foundation: achieving the mission. , 2009, Respiratory care.
[26] D. Sheppard,et al. Molecular pharmacology of the CFTR Cl- channel. , 1999, Trends in pharmacological sciences.
[27] L. Saiman,et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. , 2009, Chest.
[28] David K. Meyerholz,et al. Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs , 2008, Science.
[29] L. Saiman,et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[30] J. Clancy,et al. Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del–CFTR mutation , 2010 .
[31] D. Meyerholz,et al. Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. , 2010, The American journal of pathology.
[32] K. Southern,et al. Physiological measurements confirming the diagnosis of cystic fibrosis: the sweat test and measurements of transepithelial potential difference. , 2009, Paediatric respiratory reviews.
[33] Vicky A Legrys,et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.
[34] M. Wilschanski,et al. Pathology of pancreatic and intestinal disorders in cystic fibrosis , 1998, Journal of the Royal Society of Medicine.
[35] S. Randell,et al. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[36] S. Emerson,et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study , 2003, The Lancet.
[37] J. Davies,et al. Monitoring respiratory disease severity in cystic fibrosis. , 2009, Respiratory care.
[38] M. Buchwald,et al. CFTR Expression and Organ Damage in Cystic Fibrosis , 1994, Annals of Internal Medicine.
[39] C. Goss,et al. Patient-reported outcomes in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.
[40] J. Freyssinet,et al. Mechanisms of the noxious inflammatory cycle in cystic fibrosis , 2009, Respiratory research.
[41] J. Couzin-Frankel. Genetics. The promise of a cure: 20 years and counting. , 2009, Science.
[42] Jinglan Zhou,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[43] F. Ratjen. Cystic fibrosis: pathogenesis and future treatment strategies. , 2009, Respiratory care.
[44] M. Corey,et al. Genetic modifiers of liver disease in cystic fibrosis. , 2009, JAMA.
[45] H. Mussaffi,et al. Evidence of Intestinal Inflammation in Patients With Cystic Fibrosis , 2010, Journal of pediatric gastroenterology and nutrition.
[46] P. Merkel,et al. Consensus statement: Guide to bone health and disease in cystic fibrosis , 2005 .
[47] H. Hartung,et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. , 2010, Archives of neurology.
[48] G. McLennan,et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. , 2010, American journal of respiratory and critical care medicine.
[49] S. Paranjape,et al. Description of a standardized nutrition classification plan and its relation to nutritional outcomes in children with cystic fibrosis. , 2010, Journal of pediatric psychology.
[50] M. Gurcan,et al. Image analysis for cystic fibrosis: Automatic lung airway wall and vessel measurement on CT images , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[51] P. Sly,et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. , 2009, American journal of respiratory and critical care medicine.
[52] P. Sly,et al. Bronchiectasis in an asymptomatic infant with cystic fibrosis diagnosed following newborn screening. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[53] H. Blau,et al. Helicobacter pylori and Clostridium difficile in Cystic Fibrosis Patients , 2006, Digestive Diseases and Sciences.
[54] J. Dodd,et al. Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. , 2006, Chest.
[55] C. Planès,et al. Regulation of the epithelial Na+ channel by peptidases. , 2007, Current topics in developmental biology.
[56] W. Guggino,et al. New insights into cystic fibrosis: molecular switches that regulate CFTR , 2006 .
[57] C. Penland,et al. A pipeline of therapies for cystic fibrosis. , 2009, Seminars in respiratory and critical care medicine.
[58] Alan S. Verkman,et al. Chloride channels as drug targets , 2009, Nature Reviews Drug Discovery.
[59] J. Clancy,et al. An international randomized multicenter comparison of nasal potential difference techniques. , 2010, Chest.
[60] C. Ackerley,et al. Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise , 2010, Annals of neurology.
[61] M. de Martino,et al. Gestational and neonatal characteristics of children with cystic fibrosis: a cohort study. , 2005, The Journal of pediatrics.
[62] T. Liou,et al. Lung transplantation and survival in children with cystic fibrosis. , 2007, The New England journal of medicine.
[63] L. Tsui,et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. , 1989, Science.
[64] R. Boucher,et al. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. , 2008, Current opinion in pharmacology.
[65] M. Knowles,et al. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. , 1995, Human gene therapy.
[66] A. Horsley. Lung clearance index in the assessment of airways disease. , 2009, Respiratory medicine.
[67] R. Kronmal,et al. Advancing outcome measures for the new era of drug development in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.
[68] R. Castile,et al. Structural airway abnormalities in infants and young children with cystic fibrosis. , 2004, The Journal of pediatrics.
[69] James Rader,et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[70] M. Amaral,et al. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. , 2007, Trends in pharmacological sciences.
[71] M. Schechter,et al. Improving the quality of care for patients with cystic fibrosis , 2010, Current opinion in pediatrics.
[72] J. Clancy,et al. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. , 2007, Proceedings of the American Thoracic Society.
[73] T. Allen-Mersh,et al. Colorectal Liver Metastases: Is ‘No Treatment’ Still Best? , 1989, Journal of the Royal Society of Medicine.
[74] M. Corey. Power considerations for studies of lung function in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.
[75] M. Corey,et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. , 2006, American journal of respiratory and critical care medicine.
[76] J. Kreindler. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. , 2010, Pharmacology & therapeutics.
[77] Jonathan D. Campbell,et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. , 2005, American journal of respiratory and critical care medicine.
[78] T. Robinson. Computed tomography scanning techniques for the evaluation of cystic fibrosis lung disease. , 2007, Proceedings of the American Thoracic Society.